Nurix Therapeutics(NRIX) ZACKS·2025-04-02 15:00Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Nurix Therapeutics, Inc. despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of 13.17 million, down 20.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 3.94% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -20.47%, which indicates a bearish outlook [10][11]. Historical Performance - Nurix Therapeutics has only beaten consensus EPS estimates once in the last four quarters, with a recent surprise of -11.94% when it reported a loss of 0.67 [12][13]. Conclusion - The combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive earnings surprise for Nurix Therapeutics, suggesting that the stock may not be a compelling candidate for an earnings beat [11][16].